INT2452

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.55
First Reported 1979
Last Reported 1994
Negated 0
Speculated 0
Reported most in Abstract
Documents 9
Total Number 9
Disease Relevance 0
Pain Relevance 2.30

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lipid binding (Apoa2) protein folding (Apoa2) transport (Apoa2)
extracellular space (Apoa2) extracellular region (Apoa2) cellular_component (Apoa2)
Anatomy Link Frequency
central nervous system 1
neural 1
Apoa2 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
antagonist 3 99.80 Very High Very High Very High
Opioid 3 99.68 Very High Very High Very High
Enkephalin 4 99.60 Very High Very High Very High
Potency 2 99.60 Very High Very High Very High
narcan 22 99.28 Very High Very High Very High
electroacupuncture 7 99.20 Very High Very High Very High
Central nervous system 2 99.00 Very High Very High Very High
Morphine 3 96.84 Very High Very High Very High
tolerance 3 96.76 Very High Very High Very High
Nicotine 1 88.08 High High

|}

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The results suggest that the acceleration of the synthesis and release of AII during a long-term EA stimulation might constitute one of the mechanisms for EA tolerance.
Localization (release) of AII associated with tolerance and electroacupuncture
1) Confidence 0.55 Published 1990 Journal Sci. China, Ser. B, Chem. Life Sci. Earth Sci. Section Abstract Doc Link 2204346 Disease Relevance 0 Pain Relevance 0.49
Saralasin, an AII antagonist, blocked AII stimulation of VP release without significantly altering basal VP release by the HNS explants.
Localization (release) of AII associated with antagonist
2) Confidence 0.33 Published 1979 Journal Endocrinology Section Abstract Doc Link 446341 Disease Relevance 0 Pain Relevance 0.22
Recent reports indicate that the main effect of systemically administered angiotensin II (AII) on ACTH release is probably due to some central nervous system mechanism.
Localization (release) of AII in central nervous system associated with central nervous system
3) Confidence 0.29 Published 1986 Journal Endocrinology Section Abstract Doc Link 3015575 Disease Relevance 0 Pain Relevance 0.12
It is suggested that the endogenous release of AII and/or opioids somehow modulate basal rearing activity.
Localization (release) of AII associated with opioid
4) Confidence 0.25 Published 1994 Journal Afr J Med Med Sci Section Abstract Doc Link 7604756 Disease Relevance 0 Pain Relevance 0.17
In order to test the participation of endogenous CRF in the AII-induced ACTH release in vivo, intact and pharmacologically blocked (pretreated with chlorpromazine-morphine-nembutal) female rats were injected iv with AII (8 nmol/100 g BW).
Localization (release) of AII associated with morphine
5) Confidence 0.24 Published 1986 Journal Endocrinology Section Abstract Doc Link 3015575 Disease Relevance 0 Pain Relevance 0.14
The effects of naloxone on basal and ACTH, Angiotensin II (AII) and [K+] o stimulated aldosterone secretion from superfused rat adrenocortical tissue were investigated.
Localization (secretion) of AII associated with narcan
6) Confidence 0.16 Published 1983 Journal Life Sci. Section Abstract Doc Link 6314076 Disease Relevance 0 Pain Relevance 0.30
A potentiation of AII stimulated aldosterone secretion was observed beginning 2 hrs after 10(-6) or 10(-10) M naloxone was administered while no effect was observed with 10(-4) M naloxone.
Localization (secretion) of AII associated with narcan
7) Confidence 0.14 Published 1983 Journal Life Sci. Section Abstract Doc Link 6314076 Disease Relevance 0 Pain Relevance 0.48
The present studies were designed to test, using a combination of in vivo and in vitro paradigms, the potency of angiotensin II (AII) to release ACTH, in relation to that of other neural peptides with corticotropin-releasing activity (CRA), such as synthetic corticotropin releasing factor (CRF), arginine vasopressin (AVP) and oxytocin (OXY); and to determine whether a central or peripheral locus is the primary site of action of the peptide.
Localization (release) of AII in neural associated with potency
8) Confidence 0.13 Published 1983 Journal Neuroendocrinology Section Abstract Doc Link 6318148 Disease Relevance 0 Pain Relevance 0.09
The effect of leucine5 -enkephalin on angiotensin II (AII)-stimulated release of oxytocin and vasopressin (VP) was investigated in the conscious male rat.
Localization (release) of AII associated with enkephalin
9) Confidence 0.12 Published 1984 Journal Brain Res. Section Abstract Doc Link 6722545 Disease Relevance 0 Pain Relevance 0.28

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox